Anhui Anke Biotechnology Group

Anhui Anke Biotechnology Group is a prominent Chinese biopharmaceutical enterprise focused on the development and production of recombinant protein therapeutics and diagnostic products. Established in 1993 and headquartered in Hefei, the company is a pioneer in China's biotechnology sector, notably being among the first to be listed on the Shenzhen Stock Exchange's ChiNext board. Its core product portfolio includes recombinant human growth hormone (Ansomone) and recombinant human interferon alpha-2b (Anferon), which hold significant market shares in China. Anke Bio has expanded its strategic focus to include precision medicine, oncology, and forensic DNA testing through a network of specialized subsidiaries. The company maintains robust R&D and large-scale GMP manufacturing capabilities to support its diverse pipeline of biosimilars and innovative biologics.